HomeAI · summaries
Storia in 3 fonti
Johnson & Johnson Hits Goal With IMAAVY In Rare Blood Disorder - Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson reports Phase 2/3 data showing IMAAVY improved hemoglobin levels in wAIHA patients and secured FDA Priority Review.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune…
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an…
- ·
fiercepharma.com
J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win
Last year, Johnson & Johnson arrived late to the party with Imaavy as the third FcRn blocker
- ·
benzinga.com
Johnson & Johnson Hits Goal With IMAAVY In Rare Blood Disorder - Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson reports Phase 2/3 data showing IMAAVY improved hemoglobin levels in wAIHA patients and secured FDA Priority Review.